Enantiospecific, selective cyclooxygenase-2 inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Cyclooxygenase (COX) enzymes play critical roles in inflammation and pain.
• Non-selective COX inhibitors can lead to gastrointestinal side effects.
• Developing COX-2 selective inhibitors is a key goal in anti-inflammatory drug research.

Purpose of the Study:

• To investigate the impact of structural modifications on indomethacin alkanolamide properties.
• To explore the potential for achieving COX-2 selectivity through subtle structural changes.
• To synthesize and characterize novel indomethacin ethanolamides as potential anti-inflammatory agents.

Main Methods:

• Synthesis of novel alpha-(S)-substituted indomethacin ethanolamides.
• Stereochemical inversion at the alpha-carbon to generate R-enantiomers.
• In vitro assays to determine cyclooxygenase inhibition activity and selectivity (COX-1 vs. COX-2).

Main Results:

• Novel indomethacin alkanolamides exhibited varying degrees of cyclooxygenase inhibition.
• Stereochemical inversion from S to R configuration dramatically altered inhibitor properties.
• The R-enantiomers demonstrated potent and selective inhibition of COX-2, unlike their S-counterparts.

Conclusions:

• Subtle structural modifications, specifically stereocenter inversion, can profoundly influence the pharmacological profile of indomethacin derivatives.
• Simple stereochemical changes can transform non-selective COX inhibitors into highly COX-2 selective agents.
• These findings highlight the potential of stereochemistry in designing targeted anti-inflammatory drugs.